Saxon Interests Inc. Purchases 160 Shares of Johnson & Johnson (NYSE:JNJ)

Saxon Interests Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,890 shares of the company’s stock after purchasing an additional 160 shares during the period. Saxon Interests Inc.’s holdings in Johnson & Johnson were worth $1,309,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. MRP Capital Investments LLC increased its position in shares of Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after buying an additional 65 shares during the period. Syverson Strege & Co increased its position in shares of Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after buying an additional 65 shares during the period. Sage Mountain Advisors LLC increased its position in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after buying an additional 67 shares during the period. Sovereign Financial Group Inc. increased its position in shares of Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after buying an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc increased its position in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after buying an additional 69 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research analyst reports. Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Finally, Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Stock Down 0.2%

Shares of Johnson & Johnson stock opened at $155.59 on Thursday. The company has a market cap of $374.36 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The company’s 50 day moving average is $153.63 and its 200 day moving average is $153.88. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.34%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.